Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

Quantum-Si acquires Majelac Technologies

Quantum-Si, a Guilford-based protein sequencing company, has acquired Majelac Technologies LLC. The privately-owned Majelac, which is based in Pennsylvania, provides semiconductor packaging and integrated circuit...

| By Caitlin Truesdale

FDA may authorize Pfizer booster as early as 11/18

The FDA intends to authorize booster doses of Pfizer-BioNTech’s coronavirus vaccine for all adults as early as November 18, a move that would expand the...

| By Caitlin Truesdale

ReNetX completes enrollment in spinal cord study

ReNetX Bio has reported successful completion of patient enrollment in Part 2 of its RESET study. The RESET study (Part 2) is a multiple dose, double-blind, placebo-controlled...

| By Caitlin Truesdale

Stamford’s Cara names Christopher Posner new CEO

Stamford’s Cara Therapeutics has named Christopher Posner president and CEO, effective November 9. Posner succeeds Derek Chalmers, who will transition to a senior adviser role. Chalmers co-founded the...

| By Caitlin Truesdale

UConn professor studies trichomes in cannabis

Cannabis has been gaining more and more attention as a promising tool for the medical community. Yet much of the plant’s biology remains a mystery...

| By Caitlin Truesdale

Pfizer/Biohaven deal to market migraine drug

Pharma giant Pfizer is betting on Biohaven Pharmaceuticals and its migraine drug Nurtec ODT, also known as rimegepant, agreeing to pay $500 million upfront for the rights to commercialize...

| By Caitlin Truesdale

IsoPlexis leverages new tech to fight diseases

It has been a time of growth for Yale life sciences spinout IsoPlexis. CEO Sean Mackay co-founded the company with Rong Fan, a professor of biomedical...

| By Caitlin Truesdale

CT ‘Innovation Corridor’ may create 15K jobs

Connecticut Gov. Ned Lamont is moving ahead with a $100 million “Innovation Corridor” initiative. Lamont projects the initiative will support 15,000 new jobs over five years...

| By Kelley Gipson

AstraZeneca Imfinzi + chemo outpaces chemo alone

A combination of the AstraZeneca drug Imfinzi (durvalumab) and chemotherapy significantly extended the lives of first-line patients with advanced biliary tract cancer over chemo alone, according...